The Role of Direct Oral Anticoagulants in the Treatment of Cancer-Associated Venous Thromboembolism: Review by Middle East and North African Experts
S Bazarbashi, HM El Zawahry, T Owaidah… - Journal of Blood …, 2024 - Taylor & Francis
Venous thromboembolism is a leading cause of morbidity and mortality in patients with
active cancer who require anticoagulation treatment. Choice of anticoagulant is based on …
active cancer who require anticoagulation treatment. Choice of anticoagulant is based on …
[HTML][HTML] Risk of Venous Thromboembolism in Patients With Stage III and IV Non–Small-Cell Lung Cancer: Nationwide Descriptive Cohort Study
Background Venous thromboembolism (VTE) is a common complication in patients starting
cancer therapies for non–small-cell lung cancer (NSCLC). We examined the risk and timing …
cancer therapies for non–small-cell lung cancer (NSCLC). We examined the risk and timing …
Predicting VTE and utility of thromboprophylaxis in metastatic and recurrent cervical cancer
CA Walker, C Edwards, D McIntire, L Makepeace… - Gynecologic …, 2024 - Elsevier
Objective Patients with cervical cancer who are diagnosed with venous thromboembolism
(VTE) have worse outcomes compared to those not affected. There has yet to be a reliable …
(VTE) have worse outcomes compared to those not affected. There has yet to be a reliable …
[HTML][HTML] The Daily US News Updates
S Bazarbashi, HM El Zawahry, T Owaidah, MA AlBader… - thedailyusnews.com
Venous thromboembolism is a leading cause of morbidity and mortality in patients with
active cancer who require anticoagulation treatment. Choice of anticoagulant is based on …
active cancer who require anticoagulation treatment. Choice of anticoagulant is based on …